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Introduction: Data on patients with alpha1-antitrypsine deficiency (AATD) on long-term oxygen
therapy (LTOT) is sparse. The aim of this study was to present the incidence of patients with
AATD on LTOT, and compare their characteristics, comorbidities and prognosis (lung transplan-
tation, termination of LTOT, and survival) with COPD patients without AATD.
Methods: A National prospective study of all COPD patients who started LTOT for the first time
in the period 01.11.1994 to 31.12.2010.
Results: Among the 21,964 patients on LTOT, 234 patients had AATD. AATD patients were more
often males and were on average about 17 years younger than patients without AATD. Cardio-
vascular diseases and diabetes mellitus were significantly less prevalent among patients with
AATD (60.4% versus 70.3% (P < 0.001) and 4.7% versus 12.2% (P < 0.001)), whereas osteoporosis
was more frequent (28.5% versus 20.4%, pZ 0.002. Eighty-nine (38.0%) AATD patients and 173
(0.8%) non-AATD patients were lung transplanted in the study period.
Median survival was 8.7 years in AATD patients with lung transplantation, 3.3 years in AATD
patients without lung transplantation, 6.3 years in non-AATD patients with lung transplanta-
tion, and 1.6 years in non-AATD without lung transplantation. Even after adjustment for
gender, age, comorbidities, and the time between start of LTOT and lung transplantation, pa-
tients with AATD had a lower risk of death compared to non-AATD patients (Hazard ratio 0.73
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1190 T.J. Ringbaek et al.Conclusions: Compared with COPD without AATD, AATD patients are younger, more often
males, have a lower prevalence of cardio-vascular diseases and diabetes mellitus, and higher
prevalence of osteoporosis. Moreover, they have better prognosis, partly due to greater chance
of receiving a lung transplantation.
ª 2014 Elsevier Ltd. All rights reserved.Most knowledge on long-term oxygen therapy (LTOT) orig-
inates from patients with chronic hypoxaemia due to
obstructive pulmonary disease (COPD) [1]. A minor part of
the patients has emphysema due to alpha1-antitrypsine
deficiency (AATD). Up to date, the literature on AATD pa-
tients on LTOT is sparse and little is known on oxygen
treatment, prognosis and comorbidities in these patients
[2e4]. Two studies have shown that COPD patients with an
emphysematous phenotype had lower rates of diabetes
mellitus and cardio-vascular diseases compared to COPD
patients with a chronic bronchitis phenotype [5,6]. It can
therefore be hypothesized that, among patients with AATD
and hypoxaemia, treatment effect of LTOT, and long-term
prognosis may differ from patients without AATD.
In the present study of all Danish patients on LTOT from
1994 to 2010, we present the incidence of patients with
AATD on LTOT, and compare their characteristics, comor-
bidities, prescribed oxygen devices, and prognosis (lung
transplantation, termination of LTOT, and survival) with
COPD patients without AATD.Material
Collection of information
We used the information from the Danish Oxygen Register,
which was established in November 1994 and covers the
entire Danish population (approximately 5.6 million in-
habitants) [7].
All COPD patients who started LTOT for the first time in
the period 01.11.1994 to 31.12.2010 (N Z 21,964) were
included. Oxygen suppliers provided information on pa-
tients on home oxygen therapy, their prescriptions, and
termination of therapy. Danish guidelines on LTOT are in
accordance with international guidelines, where the cor-
nerstones are presence of hypoxaemia, non-smoking status
and usage of oxygen at least 15 h daily [8,9].
It is our impression that some Danish physicians initiate
LTOT in patients with very severe hypoxaemia with low
tobacco consumption if the patient understands not to
smoke while using oxygen.
We extracted diagnoses from The National Patient Reg-
istry [10]. COPD was defined using the 10th version of the
International Classification of diseases (ICD-10) as J40.0-
44.9, except for the first two months of the study period,
where Denmark used the ICD-8 codes (491-2). AATD pa-
tients were identified by the E88.0 code (E273.4 in the ICD-
8) and all patients with the AATD code had the diagnosis
confirmed by The Danish AATD Registry with a measurement
of the serum AAT level, where a value below 12 mmol/L
confirmed diagnosis [11]. Determination of phenotype (Pitype) was usually verified by isoelectric focussing, as
described by Fagerhol and Cox [12]. None of the patients
received AAT replacement therapy, as this treatment is not
recommended for patients with AATD in Denmark.
Data on the following COPD-related comorbidities were
collected from The National Patient Registry: cardio-
vascular diseases (CVD)(ICD-10: I00-99), hypertensive dis-
eases (I10-15), ischaemic heart diseases (I20-25), heart
failure (I50), gastro-oesophageal reflux disease (K21),
depressive disorder (F32-33), diabetes mellitus (DM)(E10-
14), and osteoporosis (M80-82). In order to test the hy-
pothesis that patients with AATD had lower BMI than pa-
tients without AATD, we included the diagnosis “obesity”
(E66).
The Danish National Lung Transplantation Program Reg-
istry gave information on lung transplantation on all COPD
patients with and without AATD. This program has been
described in detail previously [13].
Vital status was ascertained trough the National Health
Services Central Register up to December 31st, 2011. Sur-
vival rates were calculated in 21,933 patients who started
LTOT for the first time in the study period (31 patients were
excluded because the exact start date was missing). The
mean observation time of the patients was 8.6 years
(1.0e17.2 years), and 18,650 (85%) deaths were observed.
The regional Ethical Committees and the Data Inspection
Board have approved the study.
Statistics
Patients with AATD were compared to patients without
AATD. The Chi2 and two sample t-tests were used as
appropriate to compare differences between groups. Odds
ratios were calculated by logistic regression analysis.
KaplaneMeier plot was used to compare survival. Change in
proportion of patients with AATD over time was analysed by
logistic regression with calendar year as categorical vari-
able. Cox regression model was used to determine whether
AATD and lung transplantation were individual predictors of
survival.
In case of lung transplantation after start of LTOT, time
from transplantation was used to analyse survival.
Covariates in the Cox regression analyses were age
(continuous), gender, hypertensive diseases (yes/no),
ischaemic heart diseases (yes/no), heart failure (yes/no),
gastro-oesophageal reflux disease (yes/no), depressive
disorders (yes/no), diabetes mellitus (yes/no), and osteo-
porosis (yes/no). The highest bivariate correlation between
these comorbidities was r Z 0.26. We interpreted these
correlations to mean that multicollinearity was not a
concern, and therefore included the comorbidities as
separate independent variables. The results of the Cox
Table 1 Characteristics of COPD patients with and without alpha1-antitrypsine deficiency (AATD) who started long-term
oxygen therapy (LTOT) for the first time in the study period.
With Without P-level
AATD (n Z 234) AATD (n Z 21,730)
Age, years 56.5 (10.8) 73.4 (9.1) <0.001
Females 44.9% 59.2% <0.001
Flow (litre/minute) (n Z 227/21,297) 1.6 (0.8) 1.4 (0.8) 0.026
Liquid oxygen (n Z 225/21,411) 23.1% 5.4% <0.001
Mobile gas cylinders (n Z 225/21,411) 67.6% 57.2% 0.002
Prescribed oxygen hours per daya
15 81.2 86.7 0.013
<15 3.4 2.8 0.60
“As needed” 2.6 1.9 0.44
Missing 12.8 8.6 0.021
Age and oxygen flow are registered as mean (SD).
a According to the oxygen suppliers.
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tive risks (hazards ratios) with corresponding 95% confi-
dence intervals (CIs). Data analysis and descriptive
statistics were performed with the statistical package for
the social sciences (SPSS) ver. 13.0 (SPSS Inc., Chicago,
USA). A two-sided P-value of <0.05 was considered
significant.Results
In the study period of 16 years, 234 patients with AATD
started on LTOT, comprising 1.1% of all new COPD patients
on LTOT (Table 1). The phenotype (PI types) was recorded
in 224 of the AATD patients: 205 were of the phenotype ZZ,
16 SZ, two Z0, and one was MZ. The annual incidence and
proportion of AATD on LTOT decreased during the study
period (Exp (B) Z 0.94 per calendar year (95%
CI:0.92e0.97); P < 0.001) (Figure 1). AATD patients were
more often males and were on average about 17 years
younger than patients without AATD (Table 1). Moreover,
they were more often prescribed liquid oxygen and mobile
oxygen. Slightly fewer AATD patients were prescribed oxy-
gen for 15e24 h per day and correspondingly more AATD
patients had missing values for prescribed hours per day on
LTOT (Table 1).
AATD patients had significantly lower prevalence of DM
and CVD, but higher rate of osteoporosis (Table 2).
Eighty-nine (38.0%) AATD patients were lung trans-
planted in the study period, and 78 had LTOT prescribed0
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Figure 1 Incidence and proportion of alpha1-antitrypsinebefore transplantation. Two of these patients stopped LTOT
before lung transplantation. Similarly, 173 (0.8%) non-AATD
patients received lung transplantation, and 152 with LTOT
started before transplantation. Eight of these patients
stopped LTOT before lung transplantation.
It was possible for 4962 (22.6%) of the patients to stop
LTOT and stay alive without re-starting LTOT within 3
months (successful termination of LTOT). The likelihood of
“successful termination of LTOT” was 5.4-times higher for
transplanted patients (both AATD and non-AATD) compared
to non-AATD patients who were not transplanted (Table 3).
Among the transplanted patients on LTOT, significantly
more patients with AATD patients compared to non-AATD
patients had a “successful termination of LTOT” (72.4%
versus 54.2%; P < 0.001).
Patients with AATD had a better survival than patients
without AATD (Figure 2). Median survival was 8.7 years for
AATD with lung transplantation (6.0 years when time before
transplantation was excluded), 3.3 years for AATD without
lung transplantation, 6.3 years for non-AATD with lung
transplantation (3.6 years when time before lung trans-
plantation was excluded), and 1.6 years for non-AATD
without lung transplantation. When adjusting for gender,
age, and the time between start of LTOT and lung trans-
plantation, patients with AATD without transplantation had
lower risk of dying compared to non-AATD patients without
lung transplantation with hazard ratios (HR) 0.83 (95%
confidence interval (CI): 0.68e1.00; P Z 0.048). In both
groups, lung transplantation was associated with lower risk
of death (HR: 0.75 (95% CI: 0.64e0.88); P < 0.001).20
08
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deficiency (AATD) patients on LTOT from 1995 to 2010.
Table 2 Prevalence of COPD comorbidities according to alpha1-antitrypsine deficiency (AATD) status.
Co-morbidity ICD-10 Code COPD Without AATD COPD With AATD P-level
All cardio-vascular diseases I00-99 70.3% 60.4% 0.001
Hypertensive diseases I10-15 19.6% 13.6% 0.021
Ischaemic heart diseases I20-25 27.7% 12.8% <0.001
Heart failure I50 33.8% 13.2% <0.001
Gastro-oesophageal reflux disease K21 2.1% 0.9% 0.25
Depressive disorders F32-33 5.7% 4.3% 0.33
Diabetes mellitus E10-14 12.2% 4.7% <0.001
Obesity E66 4.4% 2.1% 0.11
Osteoporosis M80-82 20.4% 28.5% 0.002
Table 3 The likelihood (odds ratio) of stopping long-term oxygen therapy (LTOT) and stay alive without re-starting LTOT
within 3 months (successful termination of LTOT).
N Odds ratio (95% confidence interval)
Non-AATD and no lung transplantation 21.565a 1
AATD and no lung transplantation 147b 0.5 (0.3e0.8)
Lung transplanted while on LTOTc 220 5.4 (4.1e7.0)
AATD: alpha1-antitrypsine deficiency.
a Missing information on stopping LTOT in 64 patients.
b Missing information on stopping LTOT in one patient.
c 32 Patients started LTOT after lung transplantation or stopped LTOT before lung transplantation. They are not included in this
analysis.
1192 T.J. Ringbaek et al.Similarly, patients with AATD had a lower risk of dying
compared to patients with non-AATD, both when all pa-
tients were analysed, and when patients with lung trans-
plantation were analysed (Table 4).Figure 2 Unadjusted survival according to alpha1-anti-
trypsine deficiency (AATD) status and performed lung
transplantation.Discussion
Among COPD patients on LTOT, we found that the incidence
of AATD patients has decreased from 3.3 to 2.0 per 1 million
inhabitants from 1994 to 2010. In general, AATD patients
were younger, more often male, had lower rates of DM and
CVD and higher rate of osteoporosis. With regard to oxygen
treatment, they had higher oxygen flow prescribed, and
were more often prescribed liquid oxygen and portable
oxygen devices. Compared to non-AATD patients, AADTD
patients had better prognosis, regardless of lung trans-
plantation, comorbidities, and age.
We think that the decline in the number of patients with
AATD is caused by a decrease in smoking prevalence from
58% to 22% in Denmark from 1970 to 2010, and that this
reduction has a greater influence of the more vulnerable
AATD patients as compared to non-AATD patients.
In 1993, the Swedish Oxygen Register reported that 28
AATD patients started LTOT during an observation period of
21/2 years. This corresponds to an annual incidence of
approximately 1.5 per 1 million inhabitants [2]. This is
significantly lower than in Denmark, where we found an
incidence of 2e4 per 1 million.
CVD, DM, gastro-oesophageal reflux disease (GERD),
depressive disorder, and osteoporosis are well known
comorbidities in patients with COPD [5,6,14e18]. In the
ECLIPSE study, CVD and DM were independently associatedto increased mortality [16]. Except for a lower prevalence
of GERD, the comorbidities profile observed in our study
was consistent with what has been reported in other studies
[16,17]: CVD was present in 13e61%, arterial hypertension
in 12e61%, DM in 5e23%, depressive disorder in 10e18%,
and osteoporosis in 7e32% (5,6,14e18). A possible expla-
nation of the substantial variability in the prevalence of the
comorbidities in these studies could be differences be-
tween the studied populations with regard to the severity
of COPD and proportion of females, differences in the
definitions of comorbidities, which could be diagnosed
based on hospital contacts, based on medical treatment or
self-reported. Our data on comorbidities stem from hospital
contacts, which can explain the low prevalence of diagnosis
like GERD in contrast to heart disease.
Table 4 Risk of dying for patients with AATD compared to non-AATD patients with hazard ratios (HR) and 95% confidence
interval according to whether lung transplantation was done.
All patients, N Z 21,850 Lung transplanted, N Z 263 Lung transplanted while on LTOT, N Z 231
Non-AATD 1 1 1
AATD 0.73 (0.62e0.86) 0.72 (0.50e1.04) 0.66 (0.44e0.99)
Results of a multivariate analysis with Cox regression model. Adjustment for age, gender, hypertensive diseases, ischaemic heart dis-
eases, heart failure, gastro-oesophageal reflux disease, depressive disorders, diabetes mellitus, and osteoporosis.
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an emphysematous phenotype (AATD-status was not given),
our AATD patients had lower rates of CVD and DM [5,6].
Interestingly, although our AATD patients were significantly
younger, they had a higher prevalence of osteoporosis.
Similarly, ECLIPSE found that emphysema was present in
21.5% of the patients with osteoporosis and in 17.1% of the
patients without osteoporosis [16].
AATD was in our study associated with lower prevalence
of obesity. This is in line with Alonso et al. who found a
significantly lower BMI in patients with an emphysematous
phenotype compared to patients with bronchitis [5].
The median survival of our AATD patients without lung
transplantation was 3.3 years. This is in keeping with the
MRC study, which showed that younger (mean age 58 years)
hypoxaemic COPD patients on LTOT had a median survival
of 3e4 years [19]. Survival of our lung transplanted AATD
patients was comparable with Swedish transplanted pa-
tients with AATD [3], but better than AATD patients from
the European Lung Transplantation Register (80% versus 64%
were alive after 3 years) [20].
Less pack-years of smoking may be the explanation for
better survival in our AATD patients after adjustment for
gender, age, comorbidities, and lung transplantation.
The guidelines often state that before considering
LTOT, the patient should be clinically stable. In practice,
stable hypoxaemia should be assessed at least twice, 3
weeks apart, and within 90 days of discharge from hospital
[8,9]. As most of our patients started LTOT in connection
with hospitalisation for an exacerbation, it is not sur-
prising that as many as 22.6% had successful termination
of LTOT. Lung transplantation indeed improved the
chance of successful termination of LTOT with odds ratio
of 5.4.
The strengths of our study include a large number of
patients from three national registries, which covered all
patients in Denmark and no loss during the follow-up.
However, there are also limitations. Data on smoking
history and compliance with LTOT are only available for a
small subgroup of our patients. Undiagnosed and unre-
ported comorbidities should be considered, as we only
included comorbidities, which resulted in contact with a
hospital. This may result in underreporting, but to the same
degree in patients with and without AATD. Under-diagnosis
of AATD is well known [21,22], and as a result the World
Health Organization recommends screening for AATD in all
COPD patients [23]. In some studies, screening has detected
0.6e2.2% with AATD [24e26]. Routine screening for AATD
was not made in our study. Yet, with 1.1% of our patients
having AATD, we believe that under-diagnosis is modest in
our material, and the high proportion of AATD patientsindicates that the awareness for identifying patients with
AATD in Denmark has been high during the whole study
period.
Our study supports the importance of identifying pa-
tients with AATD even at an advanced stage of the disease
requiring long-term oxygen treatment. These patients
represent a phenotype with better survival compared with
patients with COPD without AATD, but a higher prevalence
of osteoporosis.
In conclusion, compared with COPD without AATD, AATD
patients are characterized by being younger, more often
males, and having lower prevalence of CVD and DM, but a
higher prevalence of osteoporosis. Moreover, they have
better prognosis, partly due to greater chance of getting a
lung transplantation.
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